文献速递支持与姑息治疗

Venetoclax联合阿糖胞苷±伊达比星治疗儿童复发/难治性急性髓系白血病的1期剂量递增研究

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
PubMed 文献 · Lancet Oncol · 2020-03-11

该1期剂量递增研究在美国三家医院纳入38例2-22岁复发/难治性急性髓系白血病或急性不明谱系白血病患者,评估venetoclax联合阿糖胞苷±伊达比星的安全性和活性。推荐2期剂量为venetoclax 360 mg/m2联合阿糖胞苷1000 mg/m2×8次±伊达比星12 mg/m2。在推荐2期剂量治疗的20例患者中,14例(70%,95%CI 46-88)达到完全缓解或完全缓解伴血液学不完全恢复。

要点

  • 推荐2期剂量为venetoclax 360 mg/m2联合阿糖胞苷1000 mg/m2×8次±伊达比星12 mg/m2。
  • 推荐2期剂量组完全缓解率70%(95%CI 46-88),部分缓解率10%。
  • 常见3-4级不良事件为发热性中性粒细胞减少(66%)、血流感染(16%)和侵袭性真菌感染(16%)。

核心结论

  • Venetoclax联合化疗在儿童复发/难治性急性髓系白血病中显示出安全性和活性,建议在新诊断高危儿童急性髓系白血病中测试该联合方案。

研究设计与样本

  • 1期剂量递增研究,在美国三家研究医院进行,纳入38例2-22岁复发/难治性急性髓系白血病或急性不明谱系白血病患者,其中36例接受联合治疗。

主要发现

  • 推荐2期剂量组20例中,14例(70%,95%CI 46-88)达到完全缓解或完全缓解伴血液学不完全恢复,2例(10%)达到部分缓解。
  • 最常见3-4级不良事件为发热性中性粒细胞减少22例(66%)、血流感染6例(16%)、侵袭性真菌感染6例(16%)。
  • 治疗相关死亡1例,死于结肠炎和脓毒症。

关键数值与推荐

  • 推荐2期剂量:venetoclax 360 mg/m2(最大600 mg)联合阿糖胞苷1000 mg/m2每剂共8剂,±伊达比星12 mg/m2单次。
  • 剂量递增阶段venetoclax可选240 mg/m2或360 mg/m2,阿糖胞苷可选100 mg/m2共20剂或1000 mg/m2共8剂。

临床怎么用

  • 该联合方案可作为儿童复发/难治性急性髓系白血病的潜在治疗选择,但需关注感染等不良事件。
  • 推荐在新诊断高危儿童急性髓系白血病中进一步评估该联合方案。

局限性

  • 为1期剂量递增研究,样本量小(38例),主要目的是确定推荐2期剂量和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcomes for children with relapsed or refractory acute myeloid leukaemia remain poor. The BCL-2 inhibitor, venetoclax, has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older adults for whom chemotherapy is not suitable with newly diagnosed acute myeloid leukaemia. We aimed to determine the safety and explore the activity of venetoclax in combination with standard and high-dose chemotherapy in paediatric patients with relapsed or refractory acute myeloid leukaemia. METHODS: We did a phase 1, dose-escalation study at three research hospitals in the USA. Eligible patients were aged 2-22 years with relapsed or refractory acute myeloid leukaemia or acute leukaemia of ambiguous lineage with adequate organ function and performance status. During dose escalation, participants received venetoclax orally once per day in continuous 28-day cycles at either 240 mg/m2 or 360 mg/m2, in combination with cytarabine received intravenously every 12 h at either 100 mg/m2 for 20 doses or 1000 mg/m2 for eight doses, with or without intravenous idarubicin (12 mg/m2) as a single dose, using a rolling-6 accrual strategy. The primary endpoint was the recommended phase 2 dose of venetoclax plus chemotherapy and the secondary endpoint was the proportion of patients treated at the recommended phase 2 dose who achieved complete remission or complete remission with incomplete haematological recovery. Analyses were done on patients who received combination therapy. The study is registered with ClinicalTrials.gov (NCT03194932) and is now enrolling to address secondary and exploratory objectives. FINDINGS: Between July 1, 2017, and July 2, 2019, 38 patients were enrolled (aged 3-22 years; median 10 [IQR 7-13]), 36 of whom received combination therapy with dose escalation, with a median follow-up of 7·1 months (IQR 5·1-11·2). The recommended phase 2 dose of venetoclax was found to be 360 mg/m2 (maximum 600 mg) combined with cytarabine (1000 mg/m2 per dose for eight doses), with or without idarubicin (12 mg/m2 as a single dose). Overall responses were observed in 24 (69%) of the 35 patients who were evaluable after cycle 1. Among the 20 patients treated at the recommended phase 2 dose, 14 (70%, 95% CI 46-88) showed complete response with or without complete haematological recovery, and two (10%) showed partial response. The most common grade 3-4 adverse events were febrile neutropenia (22 [66%]), bloodstream infections (six [16%]), and invasive fungal infections (six [16%]). Treatment-related death occurred in one patient due to colitis and sepsis. INTERPRETATION: The safety and activity of venetoclax plus chemotherapy in paediatric patients with heavily relapsed and refractory acute myeloid leukaemia suggests that this combination should be tested in newly diagnosed paediatric patients with high-risk acute myeloid leukaemia. FUNDING: US National Institutes of Health, American Lebanese Syrian Associated Charities, AbbVie, and Gateway for Cancer Research.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020. PMID: 32171069. doi:10.1016/S1470-2045(20)30060-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。